Author: MRN
Attending DPharm 2024 was an exciting opportunity to witness first-hand the innovation, challenges, and collaborative spirit driving the future of clinical research. From engaging keynote addresses to insightful discussions on patient-centric trials, the event highlighted a shared commitment to improving patient outcomes and advancing research.
Here are some of my key takeaways:
- A Fresh Perspective on Return on Investment in Patient-Centric Trials
Ken Getz’s insightful presentation on the short and long-term return on investment (ROI) considerations for decentralized clinical trials (DCT) was a real eye-opener. In a constantly evolving landscape, it’s clear that continuously analyzing and collaborating on our solutions is key to delivering real value. The importance of balancing innovation with tangible results was a recurring theme throughout the conference. Understanding the ROI of these solutions ensures we can sustainably impact patient care.
- Innovation Through Competition: DPHARM Idol Disrupt
One of the highlights every year is seeing emerging companies driving innovation. This year was no different, and it was inspiring to see new players like Power emerge victorious in the DPHARM Idol Disrupt competition. It’s a reminder of how vital it is to think differently and stay adaptive to new ideas and technologies in our work, ultimately helping us as a community to innovate faster and better.
- Purpose-Driven Work: Insights from Ambassador Sully Sullenberger
Ambassador Sully Sullenberger’s keynote address brought powerful insights on the importance of clarity and purpose. He shared how, in challenging moments, a clear sense of purpose brings focus, enabling us to make critical decisions effectively. It resonated deeply with the pragmatic discussions at this year’s event, reinforcing that, despite the complexity of clinical research, staying focused on the ultimate goal – improving patient outcomes – is what drives everything we do.
- Community and Compassion in Clinical Trials
The event reinforced the essential role of community – our patients, caregivers, families, and clinical teams. A moving keynote by Sarah Zenner-Dolan highlighted the human side of clinical research, including the increasing number of younger people diagnosed with Parkinson’s Disease. The message was clear: patients are the heart of clinical trials. They should not only be participants but celebrated partners in the research process. Whether through gestures as small as a “cherry pie” or heartfelt applause, their contribution must be acknowledged.
- Giving Back
A huge thank you to everyone who stopped by our booth and supported donations to Ronald McDonald House Charities! It’s always heartening to see how events like DPharm bring together individuals and companies, not just to advance research but also to give back to patients and back to our communities.
Learn more about our community-based model, how we improve recruitment and retention, and drive patient-centered solutions in clinical trials: https://themrn.io/solutions/